Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer.
But PD-1 functions can vary between different cell and cancer types, either promoting or suppressing disease progression. Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer, responds well to immune checkpoint inhibitor therapy. However, it was previously unknown if MCC cells express PD-1 themselves, and unclear how exactly cancer cell-intrinsic PD-1 contributes to tumor growth.
A study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, identified a new mechanism through which PD-1 promotes MCC progression. Through a series of experiments, the researchers demonstrated PD-1 expression on MCC cells in preclinical models and patient tumor samples. They found that MCC-PD-1 receptor binding to its ligands accelerated tumor growth by activating the mammalian target of rapamycin (mTOR) pathway and generating mitochondrial reactive oxygen species (mtROS) to promote MCC growth.
The authors subsequently showed that inhibiting mTOR signaling and neutralizing mtROS suppressed MCC-PD-1-mediated tumor proliferation in mice. These findings, they suggest, might help in the development of new treatments to halt MCC progression even in patients lacking T-cell immunity.
“For the first time, our work identifies PD-1 as an MCC-intrinsic receptor that promotes tumor growth via downstream mTOR signaling and mitochondrial reactive oxygen species production,” said corresponding author Tobias Schatton, PharmD, PhD, of the Department of Dermatology. “Targeting this tumor-intrinsic PD-1 signaling network could help optimize immune checkpoint therapy regimens and improve MCC patient outcomes.”
Read more in Science Advances .
Science Advances
Experimental study
Cells
Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling
19-Jan-2024
J.A.D. has a sponsored research agreement with Kymera Therapeutics. M.T. has served as a consultant for Incyte. C.P. received honoraria and travel support from Almirall, AbbVie, BMS, Pelpharma, Novartis, LEO Pharma, Galderma, Roche, Celgene, Iovance, SUNpharma, Sanofi Genzyme, MSD, Pfizer, and Pierre-Fabre, all unrelated to this work. The authors declare that they have no other competing interests.